The view from on high is not always clear
Stefan Stern
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The view from the top can be breathtaking, said Stefan Stern in the Financial Times. But it just as often can be distorted. According to a recent survey by the management firm Roffey Park Institute, 82 percent of corporate directors believe their organizations are in good or excellent shape. Only 52 percent of middle managers share that opinion. Similarly, more than a third of directors believe company morale is high; only 9 percent of middle managers agree. This disconnect suggests that if CEOs want to know the truth about the organizations they lead, they need to spend more time listening to middle and junior managers. Citigroup ex-CEO Charles Prince might have curbed the bank’s risky lending, for instance, if he’d kept in touch with lower-level execs who saw credit conditions deteriorating before their eyes. It’s fine for leaders to “have their eyes on the hills,” but they also need to keep “their feet on the ground."
How Big Pharma outsmarted itself
Melody Petersen
Los Angeles Times
“The strategy that has made the pharmaceutical industry one of the wealthiest and most powerful on Earth is finally starting to betray it,” said Melody Petersen in the Los Angeles Times. For the past 25 years, Big Pharma has emulated the basic business model of Hollywood—try to create
“blockbusters” by introducing products that could appeal to the masses and then “promote them like mad.” The strategy created hugely popular drugs such as the cholesterol-lowering Lipitor, Prozac for depression, and Nexium for heartburn. The problem is that as the patents on these drugs begin to expire and generic versions become available, the major drug companies “have hit a dry spell.” That’s because, in service to the blockbuster model, enormous sums were spent on promotion, “at the expense of scientific creativity.” To make that strategy work, in fact, “the drug industry put its marketers in charge; scientists were given a back seat.” And surprise, surprise: “They are not discovering enough new drugs to replace the aging standbys.”
-
Weapons: Julia Garner stars in 'hyper-eerie' psychological thrillerThe Week Recommends Zach Cregger's 'top notch' new film opens with 17 children disappearing at exactly the same time
-
Freakier Friday: Lohan and Curtis reunite for 'uneven' but 'endearing' sequelThe Week Recommends Mother-and-daughter comedy returns with four characters switching bodies
-
Al fresco art: the UK's best sculpture parksThe Week Recommends Soak up the scenery with a stroll through these open-air galleries
-
Issue of the week: Raising the minimum wagefeature How will raising the federal minimum wage from $7.25 to $9 an hour affect the economy?
-
Issue of the week: Breaking up the big banks
feature There’s a growing realization that we need to end the taxpayer guarantees that Dodd-Frank left in place.
-
Issue of the week: The death of daily deals?
feature This is a “winter of discontent” for daily deal companies Groupon and LivingSocial.
-
Issue of the week: CEOs tackle the deficit
feature America’s top business leaders sent Congress an open letter urging immediate action on the $16 trillion national debt.
-
Issue of the week: Does Wall Street need speed limits?
feature High-frequency trading now accounts for as much as 70 percent of market volume.
-
Issue of the week: Victory for a bank watchdog
feature A New York state financial regulator accused a London-based bank of laundering $250 billion for Iran.
-
Issue of the week: A former megabanker’s conversion
feature Sanford Weill, the architect of the modern megabank, now favors the end of too-big-to-fail banks.
-
Issue of the week: Libor scandal rocks banking
feature The interest rate scandal is just beginning and may soon engulf at least a dozen other major banks.